RecruitingNCT06102694
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Studying Thrombotic microangiopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Principal Investigator
- Erlie JiangChinese Academy of Medical Sciences
- Enrollment
- 500 target
- Eligibility
- 14-70 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06102694 on ClinicalTrials.govOther trials for Thrombotic microangiopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07059026Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult PatientsITAC (Instituto de Trasplantes y Alta Complejidad)
- RECRUITINGPHASE4NCT05743400Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell TransplantationHospices Civils de Lyon
- RECRUITINGNCT06759961Post-transplant Thrombotic Microangiopathy: Evaluation of Outcomes at the Bologna Kidney Transplant CentreIRCCS Azienda Ospedaliero-Universitaria di Bologna
- ACTIVE NOT RECRUITINGPHASE3NCT04543591Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantAlexion Pharmaceuticals, Inc.